WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
Coden USA: WJPRAP Impact Factor 8.453
Volume 14, Issue 21, 1204-1229. Review Article ISSN 2277–7105

ADVANCES IN ASTHMA MANAGEMENT: INTEGRATING BIOLOGICS, NANOTECHNOLOGY, DIGITAL HEALTH, AND PRECISION MEDICINE

[*1]Ramesh K., [2]Jerome Thomson, [3]Mohamed Jalaludeen, [4]Gurucharan P., [5]Pradheep K., [6]Nepolean R.

[*1]Assistant Professor, Department of Pharmacy Practice, Thanthai Roever College of Pharmacy, Tamil Nadu, India.
[2]Undergraduate Student, Department of Pharmacy Practice, Thanthai Roever College of Pharmacy, Tamil Nadu, India.
[3,4,5]Pharm D Undergraduate Student, Department of Pharmacy Practice, Thanthai Roever College of Pharmacy, Tamil Nadu, India.
[6]M Pharm, Ph.D., Professor & Principal, Department of Pharmaceutics, Thanthai Roever College of Pharmacy, Tamil Nadu, India.

Article Received on 07 October. 2025,
Article Revised on 29 October 2025,
Article Published on 01 Nov. 2025,
https://doi.org/10.5281/zenodo.17539335

***Corresponding Author**
Ramesh K.
Assistant Professor, Department of Pharmacy Practice, Thanthai Roever College of Pharmacy, Tamil Nadu, India.

How to cite this Article: [*]Ramesh K., Jerome Thomson, Mohamed Jalaludeen, Gurucharan P., Pradheep K., Nepolean R., (2025). Advances in Asthma Management: Integrating Biologics, Nanotechnology, Digital Health, and Precision Medicine. World Journal of Pharmaceutical Research, 14(21), 1204–1229.

ABSTRACT

Objective: Asthma is a heterogeneous, chronic respiratory disease with variable endotypes and significant global burden. This review aims to provide an updated synthesis of advances in asthma management, focusing on biologic therapies, nanotechnology-driven drug delivery, precision diagnostics, and digital health innovations to optimize patient outcomes. **Methods:** A thorough analysis of current literature was carried out, with a focus on asthma clinical research, immunopathology, and molecular biology. Using evidence-based data from clinical trials, translational studies, and global health reports, special attention was paid to precision medicine techniques, digital health interventions, emerging biologic therapies, and nanotechnology applications. **Results:** Advances in asthma care have enabled biomarker-guided phenotyping and targeted biologic treatments, including anti-IgE, anti-IL-5, anti-IL-4/13, and TSLP inhibitors, which improve disease control in severe and refractory cases. Nanotechnology-based delivery systems demonstrate enhanced therapeutic efficacy with reduced systemic side effects. Diagnostic innovations such as fractional exhaled nitric oxide (FeNO) testing, electronic nose (eNose) technologies, wearable acoustic sensors, and portable spirometry support early detection and personalized disease monitoring. Digital health tools, including smart inhalers, remote adherence monitoring, and artificial intelligence–driven predictive models, are transforming patient engagement and enabling proactive management. **Conclusion**: The integration of biologics, nanotechnology, precision diagnostics, and digital health has redefined asthma management, offering personalized strategies that improve outcomes for patients with severe and difficult-to-treat asthma. However, disparities in access and implementation remain significant challenges, underscoring the need for globally coordinated, evidence-based interventions.

KEYWORDS: Asthma; Precision Medicine; Biological Therapy; Nanomedicine; Inhalers; Telemedicine; Biomarkers; Medication Adherence; Global Health.

1. INTRODUCTION

Asthma is a chronic, heterogeneous inflammatory disorder of the airways that is characterized by recurrent and variable episodes of wheezing, breathlessness, chest tightness, and coughing. These symptoms often reflect variable expiratory airflow limitations, which may spontaneously reverse or improve with treatment. According to **Priya Venkatesan**, in the *2023* Global Strategy for Asthma Management and Prevention published by the Global Initiative for Asthma, more than 300 million individuals worldwide live with asthma—while many deaths are still avoidable with timely diagnosis and optimal long-term management. Her report draws on the latest high- quality evidence—including randomized controlled trials and systematic reviews—to inform global clinical practice. This highlights preferred treatment frameworks such as the ICS–formoterol “Track 1” approach, which unifies maintenance and relief therapy for better exacerbation control than SABA-only strategies do. The guidance emphasizes personalized, patient- centered care, shared decision-making, and adapting recommendations to diverse healthcare settings. The burden of asthma is notably greater in low- and middle-income countries, where gaps in diagnosis and access to essential therapies drive increased morbidity and mortality.[1] Asthma remains a significant global public health challenge, affecting an estimated 300 million individuals worldwide and contributing to substantial morbidity, mortality, and economic burden. According to Masoli et al., the global prevalence of asthma continues to rise, with considerable variations across regions due to differences in environmental exposures, genetic susceptibility, and healthcare access. Despite advancements in treatment, asthma-related deaths and hospitalizations remain largely preventable, underscoring the need for more effective management strategies tailored to individual patient needs.[2]

Over the years, a more refined understanding of the underlying **mechanisms in asthma** has emerged, particularly the distinctions between pediatric and adult-onset asthma. Barnes highlighted that while eosinophilic inflammation predominates in childhood asthma, adult forms often involve a more complex interplay of structural airway changes, neutrophilic inflammation, and corticosteroid insensitivity.[3] Recognizing these mechanistic differences has paved the way for the development of **biologic therapies** targeting specific immunological pathways, such as anti-IgE and anti-IL-5 agents, thereby moving asthma care toward precision medicine.[3]

Furthermore, Holgate elucidated the **pathogenesis of asthma** as a multifactorial process involving genetic predisposition, epithelial barrier dysfunction, immune system dysregulation, and environmental triggers.[4] Advances in nanotechnology-based drug delivery systems now allow for more targeted delivery of anti-inflammatory medications, improving airway deposition while reducing systemic side effects.[4] In addition to these innovations, **digital health technologies**, including smart inhalers and mobile health platforms, are being integrated into asthma management to facilitate real-time monitoring, enhance medication adherence, and support personalized treatment plans.

2. Aetiology and Risk Factors

The etiology of asthma is multifactorial and involves genetic predispositions, environmental exposures, and lifestyle factors. Major risk factors include the following

In addition to environmental influences and immunological mechanisms, **genetic** predispositions play crucial roles in the pathogenesis of asthma. Polymorphisms in genes associated with immune regulation, such as those encoding cytokines, chemokines, and their receptors, have been identified as significant contributors to asthma susceptibility. Furthermore, genetic variations influencing airway remodelling processes—such as genes involved in epithelial barrier function and extracellular matrix composition—have been implicated in disease progression and severity.[5] Ober and Hoffjan emphasized that asthma is a genetically complex disease with polygenic inheritance, where multiple gene–environment interactions contribute to the diverse clinical phenotypes observed across populations.[5] Despite considerable advances in genomics and bioinformatics, the translation of genetic discoveries into clinical practice remains a challenge, warranting further research to refine gene-targeted therapeutic approaches.

In addition to genetic predispositions, **environmental allergen exposure** plays a pivotal role in the initiation and exacerbation of asthma. Sensitization to common aeroallergens such as **house dust mites, pollen, animal dander, mold spores, and cockroach allergens** significantly contributes to airway inflammation and hyperresponsiveness in atopic individuals.[6] Platts-Mills emphasized that early-life exposure to these allergens, particularly in genetically susceptible individuals, increases the risk of developing persistent allergic asthma.[6] The intensity and timing of allergen sensitization influence disease severity, with perennial allergens such as dust mites having a more sustained impact on airway inflammation than does seasonal exposure to allergens such as pollen. Consequently, allergen avoidance strategies and immunotherapy have been explored as important adjuncts in comprehensive asthma management.

In addition to allergens, **environmental pollution** serves as a critical external factor influencing asthma incidence and exacerbation. Exposure to **tobacco smoke**, both prenatally and postnatally, has been strongly associated with impaired lung development and heightened airway hyperresponsiveness in children. Similarly, occupational exposure to chemical irritants, dust, and fumes in industrial environments contributes significantly to adult-onset asthma.[7] Guarnieri and Balmes reported that **urban air pollutants**, particularly particulate matter (PM2.5), nitrogen dioxide (NO_2), ozone (O_3), and sulfur dioxide (SO_2), exacerbate airway inflammation and are linked to increased hospital admissions for asthma exacerbations.[7] The synergistic effect of air pollutants with allergen sensitization further intensifies asthma severity, making environmental control measures a critical component of public health strategies aimed at reducing the asthma burden.

Respiratory infections, particularly viral infections during early childhood, have been identified as key contributors to the development and exacerbation of asthma. Viral pathogens such as **rhinovirus, respiratory syncytial virus (RSV), and influenza** can induce airway epithelial damage, enhance inflammatory responses, and promote long-term airway remodelling in genetically susceptible individuals.[8] Jackson et al. reported that severe lower respiratory tract infections in infancy significantly increase the risk of persistent wheezing and asthma development later in life.[8] Moreover, viral infections are the most common triggers of acute asthma exacerbations across all age groups, underscoring the importance of preventive strategies such as vaccination, early antiviral interventions, and the management of virus-induced inflammation in comprehensive asthma care. The comprehensive asthma management pathway explained in image 1.

3. Pathophysiology of Asthma

Asthma pathophysiology involves chronic airway inflammation, airway hyperresponsiveness, mucus hypersecretion, and airway remodelling:

A central feature of asthma pathogenesis is **airway inflammation**, which is predominantly characterized by **eosinophilic infiltration** mediated by **T-helper type 2 (Th2) cytokines**, such as **interleukin (IL)-4, IL-5, and IL-13.[9]** These cytokines orchestrate the recruitment and activation of eosinophils, promote IgE class switching in B cells, and increase mucus production, collectively contributing to airway hyperresponsiveness and remodelling. Notably, this **Th2-high inflammatory endotype** is more commonly associated with allergic asthma phenotypes and responds well to corticosteroid therapy.[9] However, advances in molecular phenotyping have revealed the existence of non-Th2 (e.g., Th17, neutrophilic) pathways in certain subsets of asthma, prompting a shift towards **endotype-driven, personalized treatment strategies**.

Airway hyperresponsiveness (AHR), defined as an exaggerated bronchoconstrictive response to various physical, chemical, or environmental stimuli, is a hallmark feature of asthma pathophysiology. The increased sensitivity of **airway smooth muscle cells** contributes to episodic airflow limitation and symptom variability, even in the absence of ongoing inflammation.[10] Holgate emphasized that structural and functional abnormalities in the **airway epithelium** play pivotal roles in amplifying AHR by facilitating the penetration of inhaled allergens, pollutants, and infectious agents into the submucosa, thereby perpetuating the inflammatory cascade.[10] Persistent AHR is closely linked to airway remodelling, highlighting the importance of early intervention to prevent long-term structural changes.

Chronic inflammation in asthma often leads to **airway remodelling**, which is characterized by structural alterations such as **subepithelial fibrosis, smooth muscle hypertrophy, goblet cell hyperplasia, and increased airway vascularity (angiogenesis).**[11] These changes contribute to **irreversible airflow obstruction** and a decline in lung function over time, particularly in patients with poorly controlled or severe asthma. Bergeron and Boulet described airway remodelling as a consequence of persistent epithelial injury and aberrant tissue repair processes that perpetuate chronic airflow limitation, independent of acute bronchoconstriction.[11] Understanding the mechanisms underlying airway remodelling is essential for developing targeted interventions aimed at halting or reversing these structural changes in asthma management.

4. Clinical features

The key clinical features of asthma include the following

Asthma is clinically characterized by **episodic symptoms**, including **wheezing, breathlessness, chest tightness, and nocturnal coughing**, which exhibit marked variability over time and in intensity.[12] Symptom exacerbation is frequently triggered by exposure to specific factors, such as **aeroallergens, physical exercise, cold air, viral infections, and environmental pollutants**. Reddel et al. highlighted that this symptom variability is a key diagnostic criterion distinguishing asthma from other chronic respiratory diseases and is closely linked to underlying airway inflammation and hyperresponsiveness.[12] Effective asthma management requires continuous assessment of symptom control and identification of trigger factors to prevent acute exacerbations and maintain optimal lung function.

5. Diagnostic Innovations in Asthma Care

5.1 Pulmonary function testing

Spirometry remains the gold standard for the **diagnosis and monitoring of asthma**, providing objective measurements of pulmonary function. Key parameters such as **forced expiratory volume in one second (FEV_1), forced vital capacity (FVC), and the FEV_1 /FVC ratio** are assessed to evaluate the presence and severity of **airflow obstruction**.[13] Pellegrino et al. outlined interpretative strategies for spirometry, emphasizing that a **reduced FEV_1 /FVC ratio**, which improves postbronchodilator use, is a hallmark of the reversible airflow limitation observed in asthma patients.[13] Regular spirometric assessments are essential for disease staging, monitoring treatment response, and differentiating asthma from other obstructive lung diseases, such as chronic obstructive pulmonary disease (COPD). In recent years, **portable spirometry devices** have been introduced to improve the accessibility of lung function testing, particularly in **primary care and resource-limited settings**. Devices such as the **Air-Smart Spirometer** offer a convenient, cost-effective alternative to traditional spirometry, enabling healthcare providers to perform reliable assessments of FEV_1 and FEV_1 /FVC ratios at the point of care.[14] Ramos-Hernández et al. validated the Air-Smart Spirometer against standard laboratory spirometry and demonstrated its accuracy and reproducibility in detecting airflow obstruction, making it a valuable tool for **early asthma diagnosis and monitoring outside specialized pulmonary clinics.**[14]

5.2 Fractional Exhaled Nitric Oxide (FeNO)

Fractional exhaled nitric oxide (FeNO) has emerged as a valuable noninvasive biomarker for assessing **airway eosinophilic inflammation** in asthma patients. Elevated FeNO levels reflect Th2-driven inflammatory activity and are particularly useful in identifying corticosteroid-responsive phenotypes.[15] Smith et al. demonstrated that incorporating FeNO measurements into asthma management strategies allowed for more precise titration of inhaled corticosteroid therapy, leading to improved asthma control and reduced exacerbation rates compared with symptom-based approaches alone.[15] FeNO testing thus serves as a practical adjunct in both diagnosis and monitoring, facilitating a **biomarker-guided, personalized treatment approach**.

5.3 Electronic nose (eNose) technology

Emerging diagnostic technologies, such as **electronic noses (eNoses),** have shown promise in the noninvasive assessment of respiratory diseases, including asthma. The eNose detects patterns of **volatile organic compounds (VOCs)** in exhaled breath, generating disease-specific **"breathprints"** that can differentiate asthma from other respiratory conditions, such as COPD or infections.[16] Dragonieri et al. highlighted the utility of eNose technology in identifying distinct VOC signatures associated with airway inflammation and oxidative stress in asthma patients.[16] Similarly, Montuschi et al. elaborated on the potential of breathomics in respiratory medicine, noting that eNose analysis offers a rapid, user-friendly, and reproducible method for early disease detection, phenotyping, and monitoring treatment response in patients with asthma.[17] While still an emerging tool, eNose technology holds significant potential in advancing personalized asthma diagnostics.

5.4 Acoustic Monitoring and Wearable Sensors

Technological advancements have facilitated the development of **wearable acoustic sensors** capable of detecting **respiratory sounds and wheezing** in real time, thereby enhancing the continuous monitoring of asthma exacerbations. Oletic and Bilas demonstrated that compressively sensed respiratory sound spectra can be effectively utilized to detect **asthmatic wheezes**, providing a foundation for noninvasive, continuous respiratory monitoring systems.[8] Similarly, Li et al. designed a wearable breathing sound monitoring system that employs advanced signal processing algorithms to detect wheezing sounds with high accuracy in daily life settings.[19] These wearable technologies offer significant potential in facilitating **early intervention during exacerbations**, improving patient adherence, and supporting remote asthma management through real-time data feedback.

6. Evolving therapeutic strategies

6.1 Pharmacological Interventions

Standard pharmacological treatment of asthma follows a **stepwise approach**, aiming to control airway inflammation, maintain lung function, and prevent exacerbations. **Inhaled corticosteroids (ICSs)** serve as the first-line **anti-inflammatory controller therapy**, particularly in patients with persistent symptoms, by reducing eosinophilic inflammation and preserving airway responsiveness. When asthma control remains inadequate with low-dose ICS alone, the addition of a **long-acting β_2 -agonist (LABA)** in combination with an ICS is preferred over increasing the steroid dose—this combination provides greater bronchodilation, reduces exacerbation rates, and improves overall disease control. For **acute relief**, **short-acting β_2 -agonists (SABAs)** remain essential, offering rapid bronchodilation for symptom rescue; however, reliance on frequent SABA usage indicates poor asthma control and necessitates escalation of anti-inflammatory therapy.[20]

6.2 Biologic therapies

Biological agents target specific immunological pathways

For patients with **moderate-to-severe allergic asthma** who remain symptomatic despite standard inhaled therapies, **omalizumab**, an anti-IgE monoclonal antibody, offers a targeted biologic approach. Omalizumab binds circulating IgE, preventing its interaction with high-affinity receptors on mast cells and basophils, thereby attenuating allergen-induced inflammatory responses.[21] Busse et al. demonstrated the efficacy of omalizumab in reducing asthma exacerbations, improving symptom control, and decreasing corticosteroid dependency in inner-city children with poorly controlled allergic asthma.[21] Omalizumab has since been established as a cornerstone biologic therapy for IgE-mediated asthma phenotypes, marking a significant advancement in **precision medicine for asthma management**.

For patients with **severe eosinophilic asthma** refractory to conventional inhaled therapies, targeted biologics directed against **interleukin-5 (IL-5)** or its receptor (IL-5R) have emerged as highly effective treatment options. **Mepolizumab** and **reslizumab** are monoclonal antibodies that neutralize IL-5, thereby reducing eosinophil survival and activity.[22,23] Pavord et al. demonstrated that mepolizumab significantly reduced exacerbation rates and improved health-related quality of life in patients with severe eosinophilic asthma.[22] Similarly, Castro et al. reported that reslizumab effectively lowered blood eosinophil counts and improved lung function in patients with poorly controlled asthma.[23] **Benralizumab**, a monoclonal antibody targeting the IL-5 receptor alpha (IL-5Rα), induces antibody-dependent cell-mediated cytotoxicity, leading to near-complete depletion of circulating eosinophils. The SIROCCO trial by Bleecker et al. confirmed its efficacy in reducing exacerbations and enhancing asthma control among patients with severe eosinophilic phenotypes.[24] These biologic agents represent major advancements in **precision medicine, offering tailored therapies for eosinophil-driven asthma endotypes**.

Dupilumab is a fully human monoclonal antibody that targets the **interleukin-4 receptor alpha (IL-4Rα)** subunit, thereby inhibiting both the **IL-4 and IL-13 signalling pathways**, which are central to the pathogenesis of type 2 (Th2-high) asthma. Wenzel et al. conducted a pivotal phase 2b trial and demonstrated that dupilumab significantly reduced asthma exacerbations, improved lung function, and allowed for corticosteroid dose reduction in patients with **uncontrolled persistent asthma** despite standard inhaled therapies.[25] Dupilumab's dual blockade of IL-4 and IL-13 offers comprehensive modulation of type 2 inflammatory responses, positioning it as a key biologic option for patients with **severe eosinophilic or oral corticosteroid-dependent asthma phenotypes**.

Tezepelumab is a first-in-class monoclonal antibody that targets **thymic stromal lymphopoietin (TSLP)**, an upstream epithelial-derived cytokine implicated in initiating and amplifying type 2 inflammatory responses in asthma. By inhibiting TSLP, tezepelumab effectively reduces airway inflammation across a broad spectrum of asthma phenotypes, including patients with **noneosinophilic (Th2-low) asthma**. The NAVIGATOR phase 3 trial, conducted by Menzies-Gow et al., demonstrated that tezepelumab significantly decreased annual asthma exacerbation rates, improved lung function, and reduced biomarkers of airway inflammation in adolescents and adults with **severe, uncontrolled asthma**.[26] Its efficacy, irrespective of baseline eosinophil counts, highlights tezepelumab's potential as a **universal anti-inflammatory therapy** for diverse asthma endotypes.

6.3 Nanotechnology in Asthma Treatment

NPs such as PLGA, chitosan, and PAMAM improve drug delivery and therapeutic outcomes in the following ways.

Nanotechnology-based drug delivery systems have emerged as innovative strategies to increase **drug bioavailability**, improve **targeted pulmonary delivery**, and minimize **systemic side effects** associated with conventional asthma medications. Nanocarriers, including nanoparticles, liposomes, and nanosuspensions, enable efficient deposition of therapeutic agents within airways, optimizing local drug concentrations while reducing systemic exposure.[27] Wang et al. highlighted the potential of nanotechnology in developing precision-targeted therapies that enhance treatment efficacy and patient adherence.[27] havna et al. demonstrated that **nanosalbutamol dry powder inhalation formulations** significantly improved bronchodilation efficiency in experimental models of bronchoconstriction, offering a promising alternative to traditional inhaler devices.[28] Furthermore, da Silva et al. elaborated on the application of nanotherapeutics in chronic respiratory diseases, emphasizing their role in improving pharmacokinetic profiles, reducing dosing frequency, and offering controlled drug release mechanisms tailored for asthma management.[29]

Recent advancements in **nanomedicine** have demonstrated that **nanosalbutamol formulations** and **polymeric nanoparticles loaded with corticosteroids** significantly increase pulmonary drug deposition, prolong therapeutic effects, and reduce dosing frequency in asthma management. Matsuo et al. investigated betamethasone phosphate encapsulated in polymeric nanoparticles and reported substantial reductions in airway hyperresponsiveness and eosinophilic infiltration in a murine asthma model, highlighting the potential of nanoparticle-based corticosteroid delivery for improving anti-inflammatory efficacy.[30] Shastri emphasized the role of **nondegradable biocompatible polymers** in creating stable, controlled-release drug carriers with high pulmonary retention, offering a versatile platform for respiratory therapeutics.[31] Furthermore, Wen et al. discussed the application of **polymer-based drug delivery systems**, noting their capacity for targeted delivery, protection of labile drugs, and modulation of release profiles, which can be adapted to chronic inflammatory diseases such as asthma.[32] These innovations in nanoparticulate drug delivery represent a transformative shift toward **precision pulmonary therapeutics** with increased bioavailability and minimized systemic toxicity.

6.4 Gene therapy approaches

Emerging **gene editing technologies**, particularly **CRISPR-Cas9**, hold transformative potential in addressing the **genetic underpinnings of asthma** by enabling precise modifications of genes involved in immune regulation, airway remodelling, and inflammatory responses. Li and Hockemeyer outlined the application of CRISPR-Cas9 in stem cell models, emphasizing its potential for translating basic genetic discoveries into targeted therapies for chronic diseases, including respiratory disorders such as asthma.[33] Cox et al. further elaborated on the therapeutic prospects of genome editing, highlighting its ability to correct disease-causing mutations at the DNA level, albeit acknowledging the technical and ethical challenges that must be addressed prior to clinical application.[34] While still in experimental stages, gene editing represents a promising frontier for **long-term, disease-modifying interventions in asthma management**.

7. Smart Inhalers and Digital Health

Smart inhalers, integrated with digital sensors, have revolutionized asthma management by enabling real-time tracking of **medication adherence** and **inhalation patterns**. These devices collect inhaler usage data, providing actionable feedback to both patients and clinicians, thereby facilitating personalized interventions aimed at improving disease control. Chan et al. reviewed the role of adherence monitoring technologies and e-health platforms in enhancing inhaler technique, adherence rates, and overall asthma outcomes.[35] Additionally, van Sickle et al. demonstrated that remote monitoring of inhaler use, coupled with weekly feedback on medication usage, led to measurable improvements in asthma control and self-management in a pilot study.[36] Smart inhaler technology represents a pivotal advancement in **digital health strategies** for asthma, offering opportunities for proactive disease monitoring and reducing the burden of uncontrolled asthma.

Digital health platforms such as **Propeller Health** have demonstrated significant success in enhancing **medication adherence**, reducing asthma **exacerbations**, and providing actionable insights through **remote monitoring**. Merchant et al. conducted a randomized clinical trial and reported that the Propeller Health asthma management system improved adherence rates and led to a reduction in rescue inhaler use among patients.[37] Similarly, Barrett et al. evaluated a mobile health intervention that provided real-time feedback on inhaler usage and environmental triggers, reporting improvements in asthma control scores and adherence metrics.[38] These mobile health (mHealth) technologies exemplify the integration of **digital therapeutics into asthma care**, promoting self-management and enabling **data-driven, individualized treatment strategies. M**odern asthma management is shown in image 2.

7.1 Telemedicine and mobile health (mHealth)

The COVID-19 pandemic accelerated the adoption of **telehealth platforms** in asthma care, facilitating **remote consultations**, **symptom monitoring**, and **patient education**. Portnoy et al. demonstrated that telemedicine visits are as effective as in-person consultations for asthma management, providing a safe and convenient alternative for routine follow-up and exacerbation monitoring.[39] Huckvale et al. conducted a systematic assessment of asthma mobile applications, highlighting their evolution in delivering personalized management tools, including digital action plans and medication reminders.[40] Moreover, Ferrante et al. emphasized the growing role of **digital health interventions in pediatric asthma**, illustrating their effectiveness in improving adherence, enhancing disease control, and empowering self-management among children and adolescents.[41] Telehealth and mobile platforms are now integral components of **modern asthma care frameworks**, ensuring continuity of care and reducing healthcare disparities.

7.2 Artificial Intelligence and Predictive Analytics

The integration of **artificial intelligence (AI)** and **machine learning (ML)** in asthma care is reshaping disease management paradigms by enabling **predictive analytics** and **personalized treatment strategies**. AI models analyse vast datasets encompassing clinical, environmental, and patient-reported information to forecast exacerbation risks and optimize therapeutic interventions. Topalovic et al. reviewed the applications of AI in respiratory medicine, underscoring its utility in enhancing diagnostic accuracy, monitoring disease progression, and supporting clinical decision-making in patients with asthma.[42] Similarly, Walsh et al. conducted a scoping review highlighting how machine learning algorithms and big data analytics are leveraged to stratify asthma phenotypes, predict treatment responses, and facilitate proactive, individualized management plans.[43] These advancements in AI-driven care are pivotal in transitioning towards a **precision medicine approach** in asthma, improving outcomes through data-informed, real-time interventions.

8. Personalized Medicine and Future Directions

Personalized asthma management leverages biomarkers, genetic profiles, and phenotypic characteristics to tailor therapeutic interventions to individual patient needs. This precision medicine approach involves the classification of asthma into distinct **endotypes**, each of which is defined by unique molecular mechanisms and clinical features. Agache and Akdis emphasized the role of endotyping allergic diseases and asthma as a foundational step toward achieving personalized treatment strategies.[44] Lotvall et al. proposed a comprehensive framework for categorizing asthma into endotypes, facilitating the development of targeted biologic therapies and improving disease outcome predictions.[45] Additionally, Ray and Koll highlighted the significance of **neutrophilic inflammation** as a distinct asthma endotype associated with greater disease severity and corticosteroid resistance, underscoring the need for phenotype-specific management approaches.[46] Personalized medicine thus represents a paradigm shift in asthma care, moving beyond symptom-based classifications towards **biomarker-driven, individualized treatment plans**.

Future directions include the following

The **development of next-generation biologics** represents a pivotal advancement in the management of **severe asthma**, offering targeted therapies that modulate specific immunological pathways beyond conventional treatments. These biologics are designed to address various asthma endotypes, including eosinophilic, allergic, and nontype 2 inflammation phenotypes, by inhibiting key cytokines, receptors, and upstream mediators of the inflammatory cascade. FitzGerald et al., in a Canadian Thoracic Society position statement, emphasized the importance of these advanced biologic agents in optimizing treatment outcomes for patients with severe, refractory asthma, recommending their integration into precision medicine frameworks on the basis of validated biomarkers and patient-specific profiles.[47] The evolution of biologics thus holds promise in transforming severe asthma care by enabling **tailored, mechanism-specific interventions**.

The integration of **omics technologies**—including genomics, transcriptomics, proteomics, metabolomics, and epigenomics—has revolutionized the approach to **comprehensive patient profiling in asthma**. By decoding complex molecular signatures and biological networks, omics-driven strategies facilitate a deeper understanding of disease heterogeneity and guide precision medicine interventions. Holgate et al. elucidated the intricate **epithelial–mesenchymal interactions** contributing to airway remodelling, highlighting how molecular insights can redefine asthma pathogenesis models.[48] Bashir et al. reviewed the transformative role of multiomics approaches in delineating asthma endotypes, identifying novel biomarkers, and enabling **personalized therapeutic targeting**.[49] The convergence of omics data with clinical phenotyping data is poised to enhance **risk stratification, treatment selection, and outcome prediction** in asthma care.

Advancements in **pharmacogenetics** are paving the way for **tailored asthma therapies** by elucidating the genetic determinants of drug response variability among individuals. Understanding polymorphisms in genes encoding drug-metabolizing enzymes, receptors, and signalling pathways facilitates the identification of patients who are more likely to benefit from specific treatments while minimizing adverse effects. Ortega et al. provided a comprehensive overview of asthma pharmacogenetics, highlighting how genetic profiling can guide the selection of **optimal pharmacologic agents** and inform dose adjustments, ultimately enhancing treatment efficacy and safety.[50] The integration of pharmacogenetic data into clinical practice is a critical component of **personalized medicine frameworks**, aiming to improve outcomes through **genotype-guided therapy customization**.

Understanding **epidemiological trends** is essential in framing global strategies for asthma prevention, diagnosis, and management. Asthma affects more than **300 million individuals worldwide**, with prevalence patterns influenced by genetic, environmental, and socioeconomic factors. Papi et al. provided a comprehensive review of global asthma epidemiology, highlighting rising prevalence rates in low- and middle-income countries and emphasizing the need for region-specific healthcare interventions.[51] Additionally, Bateman et al., through the **GINA executive summary**, outlined global asthma burden dynamics and advocated for the standardization of evidence-based management protocols to reduce morbidity and mortality associated with uncontrolled asthma.[52] These insights are crucial in informing **public health policies and international guidelines** aimed at mitigating the growing asthma burden globally.

An in-depth understanding of **the influence of pharmacogenomics** on therapy response is critical for optimizing asthma treatment strategies. Genetic polymorphisms can significantly affect how individuals respond to commonly used medications such as **beta-agonists** and **corticosteroids**, impacting both the efficacy and risk of adverse events. Israel et al. investigated the effects of regularly scheduled albuterol use, examining both **genomic and phenotypic outcomes**, and demonstrated that specific genetic variations in the **β2-adrenergic receptor gene (ADRB2)** were associated with altered therapeutic responses.[53] Such pharmacogenomic insights are essential for guiding **personalized treatment regimens**, minimizing therapeutic failure, and advancing precision medicine approaches in asthma care.

Epidemiological surveillance of asthma symptom prevalence is essential for understanding disease burden and informing global health strategies. The **International Study of Asthma**

and Allergies in Childhood (ISAAC) Phase III provided comprehensive data on worldwide trends in asthma symptoms across diverse geographic and socioeconomic contexts. Pearce et al. reported significant variability in asthma symptom prevalence among children, with notable increases observed in low- and middle-income countries, suggesting a potential influence of urbanization, environmental exposure, and underdiagnosis.[54] These findings underscore the need for **continuous monitoring, standardized diagnostic criteria, and globally coordinated interventions** to address the evolving epidemiology of asthma.

The integration of **digital self-management tools** has significantly enhanced patient engagement, self-monitoring, and adherence in asthma care. These interventions, which include smartphone applications, web-based platforms, and connected devices, empower patients with real-time symptom tracking, medication reminders, and educational resources. Morrison et al., in a systematic review, highlighted that digital self-management solutions not only improve asthma control and quality of life but also support remote monitoring and data sharing between patients and healthcare providers.[55] Such technologies are pivotal in facilitating **patient-centered care models**, enabling proactive disease management beyond traditional clinical settings.

A proper **inhalation technique** is critical for ensuring effective drug delivery in asthma management, yet incorrect usage of inhaler devices remains a widespread challenge. Structured patient education and the use of **training tools** are essential strategies to improve inhaler technique proficiency. Lavorini et al., in the ADMIT series, emphasized the importance of device-specific training interventions and demonstrated how **interactive teaching tools, demonstration devices, and checklists** significantly enhance patient adherence and medication efficacy.[56] Implementing regular inhaler technique assessments in clinical practice is vital for optimizing therapeutic outcomes and reducing the frequency of asthma exacerbations.

The application of **biomarkers** in the management of **severe asthma** has emerged as a cornerstone of precision medicine, enabling tailored therapeutic strategies on the basis of individual inflammatory profiles. Biomarkers such as **blood eosinophil counts, fractional exhaled nitric oxide (FeNO) levels, periostin levels, and serum IgE** levels facilitate the identification of specific asthma endotypes and guide the selection of biologic therapies. Khatri et al. provided a focused review highlighting the clinical utility of biomarkers in predicting treatment response, monitoring disease progression, and optimizing biologic therapy efficacy.[57] The incorporation of biomarker-driven approaches into routine clinical practice is pivotal for enhancing disease control and improving outcomes in patients with severe, refractory asthma.

Sex-based differences significantly influence the **prevalence, severity, and pathogenesis of asthma**, with distinct immunological and hormonal mechanisms contributing to these disparities. While asthma is more prevalent in males during childhood, a shift occurs postpuberty, with a higher prevalence and severity observed in females. Shah and Newcomb explored the underlying biological factors driving this sex bias, including **hormonal regulation of airway inflammation, differences in immune response modulation, and genetic susceptibility patterns**.[58] Recognizing and addressing sex-specific differences is essential for developing **sex-sensitive diagnostic criteria and personalized treatment strategies** for asthma management.

The advent of **precision medicine** in asthma care emphasizes the importance of aligning specific **phenotypes and endotypes** with targeted therapeutic interventions. Heterogeneity in clinical presentation and underlying immunopathology necessitates a shift from the traditional one-size-fits-all approach to a more individualized treatment strategy. Custovic et al. discussed how precision medicine frameworks integrate phenotypic classification—such as **eosinophilic, neutrophilic, and pauci-granulocytic asthma**—with biomarker-guided treatment selection, thereby enhancing therapeutic efficacy and reducing unnecessary medication exposure.[59] This approach is instrumental in improving patient outcomes by providing **mechanism-specific interventions tailored to individual disease profiles**.

Medication adherence is a critical determinant of asthma control, with poor adherence being a leading cause of treatment failure and exacerbation. Advances in adherence monitoring, including **smart inhalers and digital health platforms**, enable real-time tracking of medication use and facilitate timely clinical interventions. Price et al. evaluated the impact of adherence monitoring on asthma outcomes and demonstrated that structured monitoring strategies significantly improved **medication adherence and symptom control and reduced hospitalizations**.[60] The incorporation of adherence monitoring tools into routine asthma care supports a **proactive approach to disease management**, enhancing both clinical outcomes and healthcare resource utilization.

Recent paradigm shifts in asthma management advocate the use of **as-needed inhaled corticosteroid (ICS)-formoterol combinations** for patients with mild asthma, replacing traditional short-acting beta-agonist (SABA)-reliant therapy. In a large controlled trial, Beasley et al. demonstrated that compared with SABA monotherapy, **as-needed budesonide-formoterol therapy** significantly reduced the risk of severe exacerbations while maintaining symptom control.[61] This approach not only mitigates the risks associated with SABA overuse but also ensures **early anti-inflammatory intervention**, aligning with contemporary strategies for reducing asthma-related morbidity.

The **Global Asthma Report 2018**, published by the Global Asthma Network, provides comprehensive insights into the worldwide burden of asthma, highlighting significant disparities in disease prevalence, morbidity, and mortality across regions. The report underscores critical gaps in diagnosis, treatment access, and public health strategies, especially in low- and middle-income countries.[62] Addressing these challenges requires a coordinated global effort emphasizing **evidence-based guidelines, universal access to essential medications, and robust surveillance systems** to monitor disease trends.

The evolving landscape of **precision medicine in asthma** leverages advanced molecular diagnostics, endotyping, and biomarker profiling to refine treatment strategies and improve patient outcomes. Manion et al. reviewed emerging approaches, emphasizing the integration of **genomic, transcriptomic, and proteomic data** to identify novel therapeutic targets and stratify patients on the basis of disease mechanisms.[63] These advancements facilitate a shift toward **individualized, mechanism-driven therapies**, moving beyond phenotype-based classifications and allowing for more accurate prediction of treatment response and disease progression.

Nonadherence to asthma therapy remains a persistent challenge, undermining disease control and increasing healthcare burdens. Eassey et al. outlined key strategies to predict and manage treatment nonadherence, emphasizing **patient-centered communication, personalized education, shared decision-making, and leveraging digital adherence monitoring tools.**[64] Addressing both **intentional and unintentional nonadherence** through behavioural interventions and supportive care frameworks is essential to optimize therapeutic outcomes and minimize exacerbation risks in asthma patients.

Emerging evidence suggests that **autonomic nervous system dysfunction** plays a significant role in asthma pathophysiology, influencing airway tone regulation and inflammatory responses. Wang et al. reviewed the mechanisms by which autonomic imbalance, particularly **heightened parasympathetic activity and impaired sympathetic modulation**, contributes to bronchoconstriction and symptom variability in asthma.[65] Understanding the interplay between autonomic dysfunction and asthma may open new avenues for **targeted neuromodulatory therapies** aimed at improving disease control in select patient populations. Managing **difficult-to-treat asthma** in adolescents and young adults presents unique challenges, often compounded by issues such as **adherence difficulties, psychosocial factors, and transitional care gaps**. Fleming et al. highlighted the importance of a **comprehensive, multidisciplinary approach** encompassing detailed phenotyping, adherence verification, psychological support, and coordinated care pathways tailored to the adolescent age group.[66] Early intervention strategies addressing both biological and behavioral determinants are crucial for improving long-term outcomes in this vulnerable population.

The future of asthma treatment is increasingly centered around **biologics, biomarkers, and precision medicine approaches**, transforming the management of severe and refractory asthma phenotypes. FitzGerald et al. discussed the expanding landscape of **monoclonal antibodies that target key inflammatory pathways**, as well as the critical role of **biomarker-driven patient selection** in optimizing therapeutic outcomes.[67] The integration of precision medicine principles facilitates individualized treatment regimens, aiming to reduce disease burden and improve quality of life for patients with complex asthma profiles. Redefining airway diseases.[68]

While clinical trials have established the efficacy of biologics in severe asthma, **real-world data** are essential for evaluating their effectiveness across diverse patient populations. Kavanagh et al. conducted a systematic review analysing real-world outcomes of biologic therapies, highlighting improvements in **exacerbation reduction, corticosteroid-sparing effects, and quality of life enhancements**.[69] The study emphasized the need for ongoing postmarketing surveillance and **real-world evidence (RWE)** to refine patient selection criteria and optimize the clinical use of biologic agents in asthma care.

The **airway microbiome** has emerged as a key factor influencing asthma progression and lung function decline. Dysbiosis, characterized by an imbalance in microbial communities, perpetuates chronic inflammation and exacerbates airway remodelling. Martinez discussed how such **vicious cycles between microbial dysbiosis and host immune responses** contribute to accelerated deterioration of lung function in asthma patients.[70] Understanding the interplay between the microbiome and airway pathology opens new avenues for **microbiome-targeted therapies** aimed at halting disease progression.

Images

9. CONCLUSION

Asthma management has entered an era of transformation driven by **precision medicine, novel biologics, nanotechnology, and digital health innovations**. A deeper understanding of **genetic predispositions, immune mechanisms, environmental interactions, and airway remodelling** has facilitated the development of **targeted therapies**, significantly improving outcomes for patients with severe and refractory asthma phenotypes. Emerging biologics that modulate the **IgE, IL-5, IL-4/IL-13, and TSLP pathways** offer unprecedented disease control, while advances in **nanoparticle-based drug delivery systems** are enhancing therapeutic precision and reducing systemic side effects.

Innovations in **diagnostic technologies**, including **exhaled nitric oxide (FeNO), electronic nose devices, and wearable acoustic sensors**, have refined disease monitoring, enabling earlier intervention and individualized treatment adjustments. The integration of **digital health platforms, smart inhalers, remote adherence monitoring, and AI-driven predictive models** further personalizes care, improving adherence, clinical decision-making, and patient engagement.

Real-world evidence continues to validate the effectiveness of these interventions, highlighting their impact on reducing exacerbations, optimizing corticosteroid use, and improving quality of life. Simultaneously, **omics technologies, pharmacogenetics, and microbiome research** are shaping the future of asthma care by revealing new biomarkers and therapeutic targets.

Despite these advancements, significant challenges persist, including disparities in **global asthma care access**, particularly in low- and middle-income countries. Addressing these inequities requires a concerted global effort focused on **healthcare infrastructure, guideline implementation, and equitable access to advanced therapies**.

Moving forward, a multidisciplinary approach combining **technological innovation, patient-centered care, and precision medicine** is essential to address the evolving complexities of asthma and alleviate its global burden.

Image 1



Image 2



REFERENCES

1. Venkatesan P. 2023 GINA report for asthma. Lancet Respir Med., 2023 Jul; 11(7): 589. doi:10.1016/S2213-2600(23)00230-8.
2. Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy., 2004 May; 59(5): 469-78. doi:10.1111/j.1398-9995.2004.00526.x.

3. Barnes PJ. Mechanisms in asthma: differences between children and adults. Br J Pharmacol., 2015 Oct; 172(19): 4945-59. doi:10.1111/bph.12949.
4. Holgate ST. Pathogenesis of asthma. Clin Exp Allergy, 2008 Jun; 38(6): 872-97. doi:10.1111/j.1365-2222.2008.02971.x.
5. Ober C, Hoffjan S. Asthma genetics 2006: the long and winding road to gene discovery. Genes Immun, 2006 Mar; 7(2): 95-100. doi:10.1038/sj.gene.6364284.
6. Platts-Mills TA. The role of allergens in asthma. Am J Respir Crit Care Med., 2000 Sep; 162(3 Pt 2): S134-8. doi:10.1164/ajrccm.162.supplement_1.13.
7. Guarnieri M, Balmes JR. Outdoor air pollution and asthma. Lancet, 2014 May 3; 383(9928): 1581-92. doi:10.1016/S0140-6736(14)60617-6.
8. Jackson DJ, Sykes A, Mallia P, Johnston SL. Asthma exacerbations: origin, effect, and prevention. J Allergy Clin Immunol, 2011 Dec; 128(6): 1165-74. doi:10.1016/j.jaci.2011.10.024.
9. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med., 2012 May; 18(5): 716-25. doi:10.1038/nm.2678.
10. Holgate ST. The airway epithelium is central to the pathogenesis of asthma. Allergol Int., 2008 Mar; 57(1): 1-10. doi:10.2332/allergolint.R-07-154.
11. Bergeron C, Boulet LP. Structural changes in airway diseases: characteristics, mechanisms, consequences, and pharmacologic modulation. Chest., 2006 Apr; 129(4): 1068-87. doi:10.1378/chest.129.4.1068.
12. Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations. Am J Respir Crit Care Med., 2009 Jul 1; 180(1): 59-99. doi:10.1164/rccm.200801-060ST.
13. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J., 2005 Nov; 26(5): 948-68. doi:10.1183/09031936.05.00035205.
14. Ramos-Hernández C, Núñez-Fernández M, Romero-Román C, et al. Validation of the portable Air-Smart spirometer. PLoS One., 2018 Feb 15; 13(2): e0192789. doi:10.1371/journal.pone.0192789
15. Smith AD, Cowan JO, Filsell S, McLachlan C, Monti-Sheehan G, Jackson P, Taylor DR. Diagnosing and treating asthma with exhaled nitric oxide and sputum eosinophils: a randomized controlled trial. Thorax., 2005 Sep; 60(9): 753-8. doi:10.1136/thx.2004.035311.
16. Dragonieri S, Pennazza G, Carratu P, Resta O. Electronic nose technology in respiratory diseases. Lung., 2017 Apr; 195(2): 157-65. doi:10.1007/s00408-017-9985-5.

17. Montuschi P, Mores N, Trové A, Mondino C, Barnes PJ. The electronic nose in respiratory medicine. Respiration, 2012; 85(1): 72-84. doi:10.1159/000329509.
18. Oletic D, Bilas V. Asthmatic wheeze detection from compressively sensed respiratory sound spectra. IEEE J Biomed Health Inform, 2018 Sep; 22(5): 1406-14. doi:10.1109/JBHI.2017.2745420.
19. Li SH, Lin BS, Tsai CH, Lee MY, Hung CH, Lin BS. Design of wearable breathing sound monitoring system for real-time wheeze detection. Sensors (Basel), 2017 Jan 13; 17(1): 171. doi:10.3390/s17010171.
20. Papi A, Blasi F, Canonica GW, Morandi L, Richeldi L, Rossi A. Treatment strategies for asthma: reshaping the concept of asthma management. *Allergy Asthma Clin Immunol*., 2020; 16: 75. doi:10.1186/s13223-020-00472-8..
21. Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, Liu AH, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med., 2011 Mar 17; 364(11): 1005-15. doi:10.1056/NEJMoa1009705.
22. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet., 2012 Aug 18; 380(9842): 651-9. doi:10.1016/S0140-6736(12)60988-X.
23. Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomized, placebo-controlled, phase 3 trials. Lancet Respir Med., 2015 May; 3(5): 355-66. doi:10.1016/S2213-2600(15)00042-2.
24. Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomized, multicentre, placebo-controlled phase 3 trial. Lancet., 2016 Nov 26; 388(10056): 2115-27. doi:10.1016/S0140-6736(16)31324-1.
25. Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomized double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet., 2016 Jul 2; 388(10039): 31-44. doi:10.1016/S0140-6736(16)30307-5.

26. Menzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Wechsler ME, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med., 2021 May 13; 384(19): 1800-9. doi:10.1056/NEJMoa2034975.
27. Wang L, Feng M, Li Q, Wang Y, He Y, Shao J, et al. Advances in nanotechnology and asthma. Ann Transl Med., 2019 Jul; 7(12): 180. doi:10.21037/atm.2019.06.43.
28. Bhavna, Ahmad FJ, Mittal G, Jain GK, Khar RK, Ali A. Nanosalbutamol dry powder inhalation: a new approach for treating broncho-constrictive conditions. Eur J Pharm Biopharm., 2009 Jul; 71(2): 282-91. doi:10.1016/j.ejpb.2008.08.006.
29. da Silva AL, Cruz FF, Rocco PRM, Morales MM. New perspectives in nanotherapeutics for chronic respiratory diseases. Biophys Rev., 2017 Dec; 9(6): 793-803. doi:10.1007/s12551-017-0316-1.
30. Matsuo Y, Ishihara T, Ishizaki J, Takatsu M, Mizushima Y, Mizushima T. Effect of betamethasone phosphate loaded polymeric nanoparticles on a murine asthma model. Cell Immunol, 2009; 260(1): 33-8. doi:10.1016/j.cellimm.2009.08.010.
31. Shastri VP. Nondegradable biocompatible polymers in medicine: Past, present and future. Curr Pharm Biotechnol, 2003 Oct; 4(5): 331-7. doi:10.2174/1389201033692033.
32. Wen R, Umeano AC, Chen P, Farooqi AA. Polymer-based drug delivery systems for cancer. Crit Rev Ther Drug Carrier Syst. 2018; 35(6): 521-53. doi:10.1615/CritRevTherDrugCarrierSyst.2018026662.
33. Li H, Hockemeyer D. Gene editing in stem cells: from basic science to translational medicine. Annu Rev Genet., 2019; 53: 151-70. doi:10.1146/annurev-genet-112618-043215.
34. Cox DBT, Platt RJ, Zhang F. Therapeutic genome editing: prospects and challenges. Nat Med., 2015 Feb; 21(2): 121-31. doi:10.1038/nm.3793.
35. Chan AHY, Reddel HK, Apter A, Eakin MN, Riekert KA, Foster JM. Adherence monitoring and e-health: how clinicians and researchers can use technology to promote inhaler adherence for asthma. J Allergy Clin Immunol Pract., 2013 Sep-Oct; 1(5): 446-54. doi:10.1016/j.jaip.2013.06.015.
36. van Sickle D, Magzamen S, Truelove S, Morrison T. Remote monitoring of inhaled bronchodilator use and weekly feedback about asthma management: an open-group, short-term pilot study of the impact on asthma control. PLoS One., 2013 Feb 13; 8(2): e55335. doi:10.1371/journal.pone.0055335.

37. Merchant RK, Inamdar R, Quade RC. Effectiveness of population health management using the propeller health asthma platform: a randomized clinical trial. J Allergy Clin Immunol Pract., 2016 May-Jun; 4(3): 455-63. doi:10.1016/j.jaip.2015.11.022.
38. Barrett MA, Humblet O, Marcus JE, Bell DC, Chan TC, Margolis PA. Effect of a mobile health intervention on asthma control and adherence: A randomized clinical trial. J Allergy Clin Immunol Pract. 2017 Mar-Apr; 5(2): 464-470.e1. doi:10.1016/j.jaip.2016.11.022.
39. Portnoy JM, Waller M, De Lurgio S, Dinakar C. Telemedicine is as effective as in-person visits for patients with asthma. Ann Allergy Asthma Immunol. 2016 Sep; 117(3): 241-5. doi:10.1016/j.anai.2016.07.012.
40. Huckvale K, Morrison C, Ouyang J, Ghaghda A, Car J. The evolution of mobile apps for asthma: an updated systematic assessment of content and tools. BMC Med., 2015 Mar 23; 13: 58. doi:10.1186/s12916-015-0292-9.
41. Ferrante G, Licari A, Marseglia GL, Tosca MA, Pajno GB, La Grutta S. Digital health interventions in children with asthma. Clin Exp Allergy., 2021 Feb; 51(2): 212-20. doi:10.1111/cea.13783.
42. Topalovic M, Das N, Burgel PR, Daenen M, Derom E, Haenebalcke C, et al. Artificial intelligence and machine learning in respiratory medicine. ERJ Open Res., 2021 Jan; 7(1): 00855-2020. doi:10.1183/23120541.00855-2020.
43. Walsh CJ, Foley C, MacHale J, Kenny LC, Creagh T. Machine learning and big data in asthma care: a scoping review. Respir Med., 2020 Nov; 167: 105004. doi:10.1016/j.rmed.2020.105004.
44. Agache I, Akdis CA. Endotypes of allergic diseases and asthma: an important step in building blocks for the future of precision medicine. Allergol Int., 2016 Jul; 65(3): 243-52. doi:10.1016/j.alit.2016.04.011.
45. Lotvall J, Akdis CA, Bacharier LB, Bjermer L, Casale TB, Custovic A, et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol. 2011 Feb; 127(2): 355-60. doi:10.1016/j.jaci.2010.11.037.
46. Ray A, Kolls JK. Neutrophilic inflammation in asthma and association with disease severity. Trends Immunol., 2017 Dec; 38(12): 942-54. doi:10.1016/j.it.2017.07.009.
47. FitzGerald JM, Lemiere C, Lougheed MD, Ducharme FM, Dell SD, Ramsey C, et al. Recognition and management of severe asthma: a Canadian Thoracic Society position

statement. Can J Respir Crit Care Sleep Med., 2017 Oct; 1(4): 199-221. doi:10.1080/24745332.2017.1395837.

48. Holgate ST, Davies DE, Puddicombe S, Richter A, Lackie P, Lordan J, et al. Mechanisms of airway epithelial damage: epithelial–mesenchymal interactions in the pathogenesis of asthma. Eur Respir J. 2003 Dec; 22(6): 1 s-5 s. doi:10.1183/09031936.03.00074903.
49. Bashir A, Banday AZ, Shah KA, Alam MS, Rafiq S. Emerging role of omics technologies in personalized medicine of asthma. Biomed Pharmacother. 2021 Mar; 133: 110975. doi:10.1016/j.biopha.2020.110975.
50. Ortega VE, Meyers DA, Bleecker ER. Asthma pharmacogenetics and the development of genetic profiles for personalized medicine. Pharmgenomics Pers Med., 2015 Feb 2; 8: 9-22. doi:10.2147/PGPM.S49497.
51. Papi A, Brightling C, Pedersen SE, Reddel HK. Asthma. Lancet. 2018 Feb 24; 391(10122): 783-800. doi:10.1016/S0140-6736(17)33311-1.
52. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008 Jan; 31(1): 143-78. doi:10.1183/09031936.00138707.
53. Israel E, Chinchilli VM, Ford JG, Boushey HA, Cherniack R, Craig TJ, et al. Use of regularly scheduled albuterol treatment in asthma: Genomic and phenotypic outcomes. Am J Respir Crit Care Med., 2004 Oct 15; 170(8): 848-53. doi:10.1164/rccm.200401-057°C.
54. Pearce N, Aït-Khaled N, Beasley R, Mallol J, Keil U, Mitchell E, et al. Worldwide trends in the prevalence of asthma symptoms: Phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax., 2007 Sep; 62(9): 758-66. doi:10.1136/thx.2006.070169.
55. Morrison D, Wyke S, Agur K, Cameron EJ, Docking RI, MacKenzie AM, et al. Digital asthma self-management interventions: a systematic review. J Med internet Res., 2014 Feb 28; 16(2): e51. doi:10.2196/jmir.2814.
56. Lavorini F, Levy ML, Corrigan C, Crompton GK. The ADMIT series—issues in inhalation therapy. 6. Training tools for inhalation devices. Prim Care Respir J., 2010 Dec; 19(4): 335-41. doi:10.4104/pcrj.2010.00065.
57. Khatri SB, Iaccarino JM, Barochia A, Popovic B, Malinovschi A, Diamant Z, et al. Use of biomarkers in the management of severe asthma: a focused review. Lancet Respir Med., 2021 Mar; 9(3): 338-50. doi:10.1016/S2213-2600(20)30368-0.

58. Shah R, Newcomb DC. Sex bias in asthma prevalence and pathogenesis. Front Immunol, 2018 Dec 18; 9: 2997. doi:10.3389/fimmu.2018.02997.
59. Custovic A, Johnston SL, Pavord I, Gaga M. Precision medicine in asthma: linking phenotypes to targeted treatments. J Allergy Clin Immunol, 2015 Mar; 135(3): 562-71. doi:10.1016/j.jaci.2014.12.008.
60. Price D, Buhl R, Chan A, Freeman D, Sarkar R, Coutts A, et al. Adherence monitoring in asthma: exploring its impact on health outcomes. Drugs, 2018 Feb; 78(2): 167-79. doi:10.1007/s40265-017-0859-7.
61. Beasley R, Holliday M, Reddel HK, Braithwaite I, Ebmeier S, Hancox RJ, et al. Controlled trial of budesonide–formoterol as needed for mild asthma. N Engl J Med., 2019 May 23; 380(21): 2020-30. doi:10.1056/NEJMoa1901963.
62. Global Asthma Network. The Global Asthma Report 2018. Auckland, New Zealand: Global Asthma Network; 2018. ISBN: 978-0-473-45093-7.
63. Manion CR, Gottlieb DJ, Reilly JJ. New approaches to precision medicine in asthma. J Allergy Clin Immunol, 2020 Jan; 145(1): 39-48. doi:10.1016/j.jaci.2019.11.003.
64. Eassey D, Reddel HK, Ryan K, Smith L. Predicting and managing treatment nonadherence in asthma. Curr Opin Allergy Clin Immunol, 2019 Jun; 19(3): 224-31. doi:10.1097/ACI.0000000000000538.
65. Wang Z, Pianosi PT, Keogh KA, Sandroni P. Role of autonomic dysfunction in asthma. J Allergy Clin Immunol, 2018 Dec; 142(6): 1557-69. doi:10.1016/j.jaci.2018.08.01
66. Fleming L, Heaney LG, Bush A. Difficult to treat asthma in adolescents and young adults. Lancet Respir Med., 2022 May; 10(5): e23-35. doi:10.1016/S2213-2600(21)00526-6.
67. FitzGerald JM, Bateman ED, Woodcock A, Baker J, Bleecker ER, Busse WW, et al. The future of asthma treatment: biologics, biomarkers, and precision medicine. Am J Respir Crit Care Med., 2019 Mar 1; 199(5): 540-51. doi:10.1164/rccm.201807-1310PP.
68. Pavord ID, Beasley R, Agusti A, et al. After asthma: redefining airways diseases. Lancet. 2018; 391(10118): 350-400.
69. Kavanagh JE, Hearn AP, Beasley R, Shields MD, Heaney LG. Real-world effectiveness of asthma biologics: a systematic review. Clin Exp Allergy, 2021 Apr; 51(4): 493-509. doi:10.1111/cea.13831.
70. Martinez FD. Vicious circles in asthma: the microbiome and lung function decline. J Allergy Clin Immunol, 2019 Sep; 144(3): 653-4. doi:10.1016/j.jaci.2019.07.015.